Monday, 16 December 2024 10:00 AM
Class Action
NEW YORK, NY / ACCESS Newswire / December 16, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BioAge Labs, Inc. ("BioAge Labs" or "the Company") (NASDAQ:BIOA). Investors who purchased BioAge Labs securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BIOA.
Investigation Details
On December 9, 2024, BioAge Labs discontinued its STRIDES Phase 2 trial for azelaprag citing safety concerns over elevated liver transaminase levels amongst study participants. BioAge Labs had previously highlighted azelaprag's potential for patients undergoing obesity therapy with incretin drugs. Following this news, the Company shares dropped more than 76.8% on that same day.
What's Next?
If you are aware of any facts relating to this investigation or purchased BioAge Labs securities, you can assist this investigation by visiting the firm's site: bgandg.com/BIOA. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | [email protected]
SOURCE: Bronstein, Gewirtz & Grossman, LLC